Log In
BCIQ
Print this Print this
 

PEP-CMV

  Manage Alerts
Collapse Summary General Information
Company Annias Immunotherapeutics Inc.
DescriptionAutologous dendritic cells pulsed with human cytomegalovirus (CMV) phosphoprotein 65 RNA
Molecular Target Human cytomegalovirus (CMV) phosphoprotein 65 (pp65) (UL83)
Mechanism of ActionVaccine
Therapeutic Modality 
Latest Stage of DevelopmentPhase I/II
Standard IndicationBrain cancer
Indication DetailsTreat glioblastoma multiforme (GBM)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

03/12/2015

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today